109 related articles for article (PubMed ID: 28039694)
21. A recombinant immunotoxin engineered for increased stability by adding a disulfide bond has decreased immunogenicity.
Liu W; Onda M; Kim C; Xiang L; Weldon JE; Lee B; Pastan I
Protein Eng Des Sel; 2012 Jan; 25(1):1-6. PubMed ID: 22101015
[TBL] [Abstract][Full Text] [Related]
22. Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies.
Kreitman RJ
BioDrugs; 2009; 23(1):1-13. PubMed ID: 19344187
[TBL] [Abstract][Full Text] [Related]
23. Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies.
Keppler-Hafkemeyer A; Kreitman RJ; Pastan I
Int J Cancer; 2000 Jul; 87(1):86-94. PubMed ID: 10861457
[TBL] [Abstract][Full Text] [Related]
24. Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies.
Kreitman RJ
Curr Pharm Des; 2009; 15(23):2652-64. PubMed ID: 19689336
[TBL] [Abstract][Full Text] [Related]
25. Toxin-labeled monoclonal antibodies.
Kreitman RJ
Curr Pharm Biotechnol; 2001 Dec; 2(4):313-25. PubMed ID: 11762413
[TBL] [Abstract][Full Text] [Related]
26. Initial characterization of an immunotoxin constructed from domains II and III of cholera exotoxin.
Sarnovsky R; Tendler T; Makowski M; Kiley M; Antignani A; Traini R; Zhang J; Hassan R; FitzGerald DJ
Cancer Immunol Immunother; 2010 May; 59(5):737-46. PubMed ID: 20091030
[TBL] [Abstract][Full Text] [Related]
27. Primate antibody response to immunotoxin: serological and computer-aided analysis of epitopes on a truncated form of Pseudomonas exotoxin.
Roscoe DM; Jung SH; Benhar I; Pai L; Lee BK; Pastan I
Infect Immun; 1994 Nov; 62(11):5055-65. PubMed ID: 7927788
[TBL] [Abstract][Full Text] [Related]
28. Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity.
Tsutsumi Y; Onda M; Nagata S; Lee B; Kreitman RJ; Pastan I
Proc Natl Acad Sci U S A; 2000 Jul; 97(15):8548-53. PubMed ID: 10890891
[TBL] [Abstract][Full Text] [Related]
29. Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox.
Kreitman RJ; Pastan I
Clin Cancer Res; 2011 Oct; 17(20):6398-405. PubMed ID: 22003067
[TBL] [Abstract][Full Text] [Related]
30. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies.
Kreitman RJ; Wilson WH; White JD; Stetler-Stevenson M; Jaffe ES; Giardina S; Waldmann TA; Pastan I
J Clin Oncol; 2000 Apr; 18(8):1622-36. PubMed ID: 10764422
[TBL] [Abstract][Full Text] [Related]
31. An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies.
Bera TK; Onda M; Kreitman RJ; Pastan I
Leuk Res; 2014 Oct; 38(10):1224-9. PubMed ID: 25127689
[TBL] [Abstract][Full Text] [Related]
32. Immunotoxins in the treatment of hematologic malignancies.
Kreitman RJ; Pastan I
Curr Drug Targets; 2006 Oct; 7(10):1301-11. PubMed ID: 17073592
[TBL] [Abstract][Full Text] [Related]
33. Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment.
Reiter Y; Pai LH; Brinkmann U; Wang QC; Pastan I
Cancer Res; 1994 May; 54(10):2714-8. PubMed ID: 8168102
[TBL] [Abstract][Full Text] [Related]
34. Simultaneous removal of T and B cell epitope in recombinant staphylokinase by structure-based mutagenesis of immuno-dominant Arg77 and Glu80 residues.
Xu R; He J; Jia K; Chen X; Liu J; Zhu K
Wei Sheng Wu Xue Bao; 2011 May; 51(5):692-703. PubMed ID: 21800633
[TBL] [Abstract][Full Text] [Related]
35. Strategies to Reduce the Immunogenicity of Recombinant Immunotoxins.
Mazor R; King EM; Pastan I
Am J Pathol; 2018 Aug; 188(8):1736-1743. PubMed ID: 29870741
[TBL] [Abstract][Full Text] [Related]
36. Purification of clinical-grade disulfide stabilized antibody fragment variable--Pseudomonas exotoxin conjugate (dsFv-PE38) expressed in Escherichia coli.
Jiang H; Xie Y; Burnette A; Roach J; Giardina SL; Hecht TT; Creekmore SP; Mitra G; Zhu J
Appl Microbiol Biotechnol; 2013 Jan; 97(2):621-32. PubMed ID: 22890777
[TBL] [Abstract][Full Text] [Related]
37. Recombinant immunotoxins for treating cancer.
FitzGerald DJ; Kreitman R; Wilson W; Squires D; Pastan I
Int J Med Microbiol; 2004 Apr; 293(7-8):577-82. PubMed ID: 15149034
[TBL] [Abstract][Full Text] [Related]
38. Technology evaluation: BL22, NCI.
Barth S
Curr Opin Mol Ther; 2002 Feb; 4(1):72-5. PubMed ID: 11883697
[TBL] [Abstract][Full Text] [Related]
39. Construction and characterization of monoclonal antibodies against the extracellular domain of B-lymphocyte antigen CD20 using DNA immunization method.
Khademi F; Mostafaie A; Parvaneh S; Gholami Rad F; Mohammadi P; Bahrami G
Int Immunopharmacol; 2017 Feb; 43():23-32. PubMed ID: 27939822
[TBL] [Abstract][Full Text] [Related]
40. Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy.
Wei H; Xiang L; Wayne AS; Chertov O; FitzGerald DJ; Bera TK; Pastan I
Proc Natl Acad Sci U S A; 2012 May; 109(18):6898-903. PubMed ID: 22509046
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]